Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

>2 years Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Partially Remote Standard Medicines InjectionEndocrinologyOphthalmology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Efgartigimod Alfa

Efgartigimod alfa is a substance that lowers harmful antibodies to treat autoimmune conditions such as generalized myasthenia gravis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann

Ophthalmology

Jette, Belgium

Cliniques Universitaires Saint-Luc

Ophthalmology

Sint-Stevens-Woluwe, Belgium

Medical Centre Oxycom OOD

Complex Izgrev, bl. 28 A, ground floor, 8000 Burgas, Bulgaria

Burgas, Bulgaria

Sponsor: Argenx

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.